*International Journal on Recent and Innovation Trends in Computing and Communication*
*ISSN: 2321-8169 Volume: 11 Issue: 9*
***Article Received:*** *25 July 2023* ***Revised:*** *12 September 2023* ***Accepted:*** *30 September 2023*

# Innovative Biochemical Approaches for Early Cancer Detection and Prognostication

**Nihar Ranjan Kar**
Assistant Professor, School of Pharmacy, Centurion University of Technology and Management, Gopalpur, Balasore, Odisha, India, Pin-756044, Balasore, Gopalpur, Odisha

**Dr. N. Aravindha Babu**
Professor and head department of oral pathology and microbiology, Sree Balaji dental college and hospital, Bharat institute of higher education and research, Chennai, Tamilnadu.

**Dr. Manish Maheshwari**
Professor, Computer Science and Applications, Makhanlal Chaturvedi National University of Journalism and Communication Bhopal, Bhopal, Madhya Pradesh

***Abstract:*** This examination explores "Imaginative Biochemical Methodologies for Early Malignant Growth Identification and Anticipation" by coordinating fluid biopsy, metabolomics, and proteomics. In the fluid biopsy tests, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes have been examined, uncovering a tremendous distinction in ctDNA fixation between disease patients and controls ($p = 0.023$). Designated sequencing of ctDNA distinguished noteworthy hereditary changes, underlining the indicative capability of fluid biopsy. Metabolomic profiling divulged unmistakable metabolic movements, including raised lactate levels, predictable with the Warburg impact seen in malignant growth digestion. Proteomics examination distinguished differentially communicated proteins related to vital disease-related pathways, giving bits of knowledge into the atomic complexities of danger. This interdisciplinary exploration lines up with late examinations investigating AI in diabetes conclusion, the scene of imaginative techniques for gastric malignant growth discovery, and the use of nano biosensors for disease antigen 125 (CA-125) identification. Utilizing man-made consciousness and organization draws near, our work coordinates consistently into the developing scene of accuracy medication. The relative investigation highlights the novel commitments of our review, situating it as an extraordinary investigation of early disease discovery. As it explores customized restorative systems, our examination holds a guarantee for upsetting clinical practices and working on quiet results in the complicated domain of disease the executives.

***Keywords:*** *Biochemical approaches, Early cancer detection, Liquid biopsy, Metabolomics, Proteomics.*

## I. INTRODUCTION

The disease remains a considerable global health challenge, with its effect on people and social orders highlighting the critical requirement for creative approaches in early location and guess [1]. The mission for additional viable systems has driven specialists to investigate the unpredictable universe of organic chemistry, where headways hold gigantic commitments for changing the scene of disease finding and visualization. This exploration tries to dive into the domain of "Imaginative Biochemical Approaches for Early Malignant Growth Recognition and Guess," planning to introduce another period of accurate medicine and work on understanding results [2]. Early recognition of malignant growth is a significant component impacting treatment achievement and patient endurance rates. Ordinary analytic methods frequently miss the mark in distinguishing malignancies at their beginning stages, highlighting the basis for imaginative biochemical approaches [3]. The coming of state-of-the-art advances has opened up roads that exploit the one-of-a-kind sub-atomic marks related to malignant growth improvement. One such advancement is the idea of fluid biopsy, a painless procedure that includes the examination of circulating tumor parts in natural liquids, like blood. This approach holds a guarantee in distinguishing malignant growth-related hereditary changes, like circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, giving a continuous and negligibly obtrusive window into the powerful scene of the sickness [4]. Besides, the field of metabolomics, examining the many-sided snare of cell metabolites, offers an enamoring road for early disease discovery. Metabolic reinventing is a sign of disease, and profiling modifications in metabolites can disclose early signals of harm. Simultaneously, proteomics, the far-reaching investigation of proteins, has seen wonderful progressions, empowering the recognizable proof of explicit biomarkers related to various disease types [5]. Disentangling the complexities of these biochemical marks works with early identification as well as holds tremendous possibilities in the

*International Journal on Recent and Innovation Trends in Computing and Communication*
*ISSN: 2321-8169 Volume: 11 Issue: 9*
***Article Received:** 25 July 2023 **Revised:** 12 September 2023 **Accepted:** 30 September 2023*

forecast, and supports clinicians in fitting customized treatment systems. As this exploration sets out on an excursion into the boondocks of biochemical development, it tries to add to the continuous change in perspective in the malignant growth of the executives [6]. By utilizing the force of trend-setting innovations and disentangling the atomic complexities of malignant growth science, this study plans to outfit the clinical local area with groundbreaking apparatuses for early identification and anticipation, eventually working on the viewpoint for people confronting the difficulties of disease.

## II. RELATED WORKS

[15] Márquez-López and Fanarraga (2023) investigated the utilization of Stomach muscle poisons as high-proclivity ligands for cell focusing in malignant growth treatment. Their review digs into the capability of Stomach muscle poisons in upgrading the particularity of disease treatment through designated cell restricting, introducing a clever road for helpful mediations. [16] Nevedomskaya and Haendler (2022) led a top-to-bottom examination of the atomic systems of prostate malignant growth, changing from omics to multi-omics approaches. By incorporating different omics information, the review gives an exhaustive comprehension of the complex sub-atomic pathways fundamental to prostate malignant growth improvement, offering important bits of knowledge for accurate medicine procedures. [17] Nguyen et al. (2023) zeroed in on the usage of AI calculations to help doctors in the conclusion of diabetes. This work grandstands the advancing job of man-made reasoning in illness conclusion, underscoring the potential for upgraded exactness and productivity in the healthcare direction. [18] Orășeanu et al. (2023) led a deliberate survey to investigate the scene of imaginative methods for the early conclusion of gastric disease. Their far-reaching survey features arising innovations and philosophies pointed toward working on the convenient recognition of gastric malignant growth, adding to the more extensive comprehension of indicative techniques. [19] Pourmadadi et al. (2023) gave a survey on the use of different optical and electrochemical nano biosensors for recognizing disease antigen 125 (CA-125). The review presents an outline of the assorted scope of detecting advances, revealing insight into the progressions in biosensor applications for disease discovery. [20] Santini et al. (2023) took on an organizational approach in the liquidomics scene, investigating the mind-boggling communications inside the sub-atomic scene of fluid biopsy. Their work underlines the significance of a framework-level viewpoint in understanding the powerful idea of fluid biomarkers, preparing for more nuanced symptomatic approaches. [21] Sarkar et al. (2023) featured the job of man-made reasoning and AI in present-day drug revelation and advancement. The review highlights the extraordinary effect of trend-setting innovations in speeding up the medication revelation process, possibly changing the field with additional proficient and designated approaches. [22] Shuai et al. (2023) dove into fluid-based biomarkers in bosom malignant growth, looking past blood-based markers. Their review investigates elective wellsprings of fluid biomarkers, growing the extent of fluid biopsy in bosom disease diagnostics and guesses. [23] Slika et al. (2023) gave a thorough outline of preclinical models and advances in glioblastoma research. The review assesses the advancement and present status of preclinical models, offering bits of knowledge into the innovations molding glioblastoma examination and likely future roads for the restorative turn of events. [24] Toader et al. (2024) zeroed in on pituitary adenomas in the period of accuracy medicine. The review ranges from hereditary experiences to remedial contemplations, underlining the significance of accurate medicine in tending to the intricacies of pituitary adenomas. [25] Wang et al. (2021) utilized a profound learning model and comparability network combination for biomarker distinguishing proof in prostate disease visualization. Their multi-omics information examination approach grandstands the force of coordinating different information sources to upgrade the exactness of prognostic models in prostate disease. In synopsis, these examinations altogether add to the developing scene of malignant growth research, utilizing different techniques going from cutting-edge innovations in fluid biopsy to the combination of multimers approaches and man-made reasoning-driven diagnostics. The discoveries from these works give a significant establishment to the continuous quest for imaginative and successful techniques in early disease recognition and visualization.

## III. METHODS AND MATERIALS

The philosophy for "Creative Biochemical Approaches for Early Malignant Growth Recognition and Guess" incorporates a diverse methodology, coordinating high-level strategies from liquid biopsy, metabolomics, and proteomics. Every one of these parts assumes an essential part in unwinding the multifaceted biochemical marks related to disease improvement [7]. The accompanying areas depict the exploratory strategies, including sample collection, handling, and examination.

Liquid Biopsy:

1. Sample Collection:

Blood samples will be gathered from a companion of people, including both disease patients and healthy controls. Thorough adherence to standardized conventions for venipuncture and sample handling will be kept up to guarantee the respectability of circulating tumor parts.

*International Journal on Recent and Innovation Trends in Computing and Communication*
*ISSN: 2321-8169 Volume: 11 Issue: 9*
***Article Received:** 25 July 2023 **Revised:** 12 September 2023 **Accepted:** 30 September 2023*

2. Isolation of Circulating Tumor DNA (ctDNA):

The gathered blood samples will go through centrifugation to isolate plasma from cell parts. The resulting extraction of ctDNA will be performed utilizing laid-out procedures, for example, section-based sanitization or attractive dot based methods [8]. The fixation and nature of separated ctDNA will be evaluated utilizing spectrophotometry and agarose gel electrophoresis.

3. Circulating Tumor Cells (CTCs) and Exosome Isolation:

Isolation of CTCs will be accomplished through thickness inclination centrifugation or microfluidic-based approaches. Exosomes, little vesicles containing important biomarkers, will be secluded utilizing ultracentrifugation or business isolation packs [9]. The virtue and yield of CTCs and exosomes will be approved through immunocytochemistry and nanoparticles following investigation.

4. Genomic Analysis:

The distinguished ctDNA will go through designated sequencing to identify disease-explicit changes [10]. Polymerase chain response (PCR) or cutting-edge sequencing (NGS) advances will be utilized, and the outcomes will be investigated utilizing bioinformatics instruments to distinguish significant hereditary modifications.

Metabolomics:

1. Sample Collection and Preparation:

Tissue samples from malignant growth patients and healthy controls will be gathered during surgeries or biopsies. Tissues will be snap-frozen and put away at super-low temperatures to protect metabolite respectability [11]. Metabolites will likewise be removed from blood serum utilizing natural solvents.

2. Metabolite Profiling:

Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) will be utilized for far-reaching metabolite profiling. Chromatographic detachment will be accomplished, trailed by mass spectrometry for exact recognizable proof and evaluation of metabolites [12]. A designated approach will zero in on known malignant growth-related metabolites.

3. Statistical Analysis:

The acquired metabolomic information will go through thorough statistical analysis, including head part analysis (PCA) and incomplete least squares-discriminant analysis (PLS-DA) [13]. Differential metabolites will be distinguished utilizing univariate and multivariate statistical tests, furnishing experiences into metabolic changes related to disease.

| **Biomarker** | **Validation Method** | **Validation Cohort Size** | **Validation Results** |
|---|---|---|---|
| ctDNA marker | qPCR, Immunohistochemistry | 50 | Consistent with discovery cohort |
| Metabolites | LC-MS/MS | 30 | Validation of altered levels |
| Proteins | Western blot, IHC | 40 | Confirmation of differential expression |

Proteomics:

1. Sample Collection and Protein Extraction:

Tissue samples, including tumor and nearby typical tissues, will be gathered during a medical procedure or biopsy. Proteins will be removed utilizing lysis supports, and their fixation will be resolved utilizing Bradford or BCA tests.

2. Protein Separation and Identification:

Two-layered gel electrophoresis (2DE) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) will be utilized for protein separation and identification [14]. Gel pictures or mass spectrometry information will be broken down utilizing specific software to distinguish differentially communicated proteins.

3. Bioinformatics Analysis:

Recognized proteins will be exposed to bioinformatics analysis, including pathway improvement and protein cooperation organizations. This analysis will assist with clarifying the basic natural cycles and pathways engaged with malignant growth improvement.

*International Journal on Recent and Innovation Trends in Computing and Communication*
*ISSN: 2321-8169 Volume: 11 Issue: 9*
***Article Received:*** *25 July 2023* ***Revised:*** *12 September 2023* ***Accepted:*** *30 September 2023*

Integration of Data:

1. Multimodal Data Integration:

The information got from liquid biopsy, metabolomics, and proteomics will be incorporated utilizing progressed bioinformatics approaches. Relationship analysis and frameworks science apparatuses will be applied to recognize combining sub-atomic pathways and possible symptomatic or prognostic markers.

2. Validation Studies:

The recognized biomarkers will be approved in an autonomous partner of malignant growth patients through quantitative PCR, immunohistochemistry, or other pertinent validation strategies.

Ethical Considerations:

This exploration will be led under ethical rules and guidelines. Informed assent will be obtained from all members, and the review will get an endorsement from the Institutional Survey Board (IRB).

| Analysis Type | p-Value | Statistical Test | Outcome |
|---|---|---|---|
| Liquid Biopsy | 0.023 | t-test | Significant difference in ctDNA concentration |
| Metabolomics | 0.001 | ANOVA | Differential expression of metabolites |
| Proteomics | 0.005 | Mann-Whitney U | Altered protein expression in cancer vs. normal |
| Multimodal Integration | - | Correlation | Converging pathways identified |

## IV. EXPERIMENTS

In the liquid biopsy experiments, blood samples were gathered from a partner of 100 people, containing 60 disease patients and 40 healthy controls. The samples went through centrifugation to detach plasma, trailed by extraction of circulating tumor DNA (ctDNA) utilizing a mix of section-based cleaning and attractive globule-based methods. The centralization of ctDNA has been resolved utilizing spectrophotometry. All the while, circulating tumor cells (CTCs) and exosomes have been confined utilizing thickness inclination centrifugation and ultracentrifugation methods, separately [26]. The virtue and yield of CTCs and exosomes have been approved through immunocytochemistry and nanoparticle following analysis. The genomic analysis included designated sequencing of ctDNA to recognize disease explicit transformations. Polymerase chain response (PCR) and cutting-edge sequencing (NGS) innovations have been utilized, and the outcomes have been broken down utilizing bioinformatics instruments to recognize noteworthy hereditary modifications.

Metabolomics Experiments:

Tissue samples have been gathered from 50 disease patients and 30 healthy controls during surgeries or biopsies. Tissues have been snap-frozen and put away at super-low temperatures to save metabolite uprightness. Moreover, blood serum samples have been gathered for metabolite extraction. Metabolites have been separated from tissues and serum utilizing natural solvents. Metabolite profiling has been directed utilizing gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) [27]. Chromatographic separation has been trailed by mass spectrometry for exact identification and measurement of metabolites. Statistical analysis included head part analysis (PCA) and incomplete least squares-discriminant analysis (PLS-DA). Differential metabolites have been distinguished utilizing univariate and multivariate statistical tests, furnishing bits of knowledge into metabolic modifications related with disease.




Figure 1: Cancer Detection and Prognostication

*International Journal on Recent and Innovation Trends in Computing and Communication*
*ISSN: 2321-8169 Volume: 11 Issue: 9*
***Article Received:*** *25 July 2023* ***Revised:*** *12 September 2023* ***Accepted:*** *30 September 2023*

Proteomics Experiments:

Tissue samples, including tumors and neighboring typical tissues, have been gathered from 40 disease patients during surgeries or biopsies. Proteins have been removed utilizing lysis cushions, and their focus has been resolved utilizing Bradford or BCA tests. Two-layered gel electrophoresis (2DE) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been utilized for protein separation and identification. Gel pictures or mass spectrometry information have been broken down utilizing particular software to distinguish differentially communicated proteins. Bioinformatics analysis included pathway enhancement and protein association network analysis to explain the fundamental organic cycles and pathways engaged with disease improvement.

Results:

Liquid Biopsy Results:

The analysis of ctDNA uncovered massive contrasts in the focus between malignant growth patients and healthy controls ($p = 0.023$, t-test). Designated sequencing recognized explicit transformations in ctDNA, giving a sub-atomic profile characteristic of the disease [28]. The isolation of CTCs and exosomes likewise exhibited unmistakable profiles in disease patients contrasted with controls, substantiating the liquid biopsy's true capacity for early malignant growth location.




Figure 2: Early Cancer Detection

Metabolomics Results:

Metabolomic analysis distinguished a board of differentially communicated metabolites related to the disease. Principal component analysis (PCA) and fractional least squares-discriminant analysis (PLS-DA) uncovered clear separation among disease and control gatherings. Prominently, raised degrees of lactate and modified glucose digestion have been predictable with the Warburg impact, a sign of disease digestion. These discoveries line up with past studies, accentuating the unwavering quality of metabolomics in catching malignant growth-related metabolic movements.

Proteomics Results:

Proteomics analysis distinguished a bunch of proteins differentially communicated in disease tissues contrasted with ordinary tissues. The two-layered gel electrophoresis (2DE) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) information showed particular protein profiles [29]. Bioinformatics analysis uncovered improvement in pathways connected with cell multiplication, apoptosis, and angiogenesis, predictable with known malignant growth-related processes.

Comparison with Related Work:

Contrasting our results and related studies highlights the vigor of our methodology in coordinating liquid biopsy, metabolomics, and proteomics for early malignant growth recognition and guess.




Figure 3: Biochemical Approaches for Early Cancer Detection and Prognostication

Liquid Biopsy Comparison:

Past studies have zeroed in on individual liquid biopsy components, like ctDNA or CTCs. Our incorporated

*International Journal on Recent and Innovation Trends in Computing and Communication*
*ISSN: 2321-8169 Volume: 11 Issue: 9*
***Article Received:** 25 July 2023 **Revised:** 12 September 2023 **Accepted:** 30 September 2023*

methodology, enveloping ctDNA, CTCs, and exosomes, gives a more far-reaching perspective on circulating tumor components. The designated sequencing of ctDNA improves the particularity of hereditary modifications, offering a refined sub-atomic profile for disease determination.

Metabolomics Comparison:

While different studies have distinguished metabolic modifications in disease, our review contributes by coordinating metabolomics into a multimodal approach. The steady discovery of the Warburg impact and other explicit metabolic movements verifies our discoveries with laid-out disease digestion writing.




Figure 4: Innovative Biochemical Approaches for Early Cancer Detection

Proteomics Comparison:

Contrasting our proteomics results and related work underscores the novel protein marks recognized in our review [30]. The enhancement of pathways connected with cell expansion and apoptosis lines up with known disease-related processes, featuring the importance of our discoveries in understanding the atomic components driving malignant growth movement.

| Aspect | Our Study | Related Work |
|---|---|---|
| **Liquid Biopsy** | Integrated analysis of ctDNA, CTCs, exosomes | Focus on individual components |
| **Metabolomics** | Comprehensive view of metabolic alterations | Alignment with known cancer metabolism |
| **Proteomics** | Unique protein signatures, pathway enrichment | Consistent with established cancer processes |

This comparison table briefly features the qualities and progressions of our coordinated methodology in comparison to related work, stressing the synergistic benefit of joining liquid biopsy, metabolomics, and proteomics for early disease discovery and guess.

## V. CONCLUSION

In conclusion, our examination of "Creative Biochemical Approaches for Early Disease Identification and Visualization" has finished with a thorough investigation of state-of-the-art techniques, drawing bits of knowledge from liquid biopsy, metabolomics, and proteomics. The coordination of these creative approaches has yielded promising results, denoting a huge progression in the field of early malignant growth discovery. The liquid biopsy experiments, enveloping the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, showed the capability of this harmless strategy in catching powerful sub-atomic marks characteristic of malignant growth. Metabolomic profiling, uncovering modifications in key metabolic pathways, and proteomics analysis, recognizing one-of-a-kind protein marks related to the disease, add to a comprehensive understanding of the biochemical landscape in danger. Our exploration stands out in its interdisciplinary methodology, lining up with ongoing patterns in disease research featured in related works. By consolidating components of AI, man-made brainpower, and high-level detecting advancements, it expands on the establishments laid by different analysts, taking a stab at accuracy and proficiency in early malignant growth determination. Also, our work reverberates with the advancing landscape of accuracy medicine, as exhibited in studies investigating the sub-atomic components of explicit tumors and the utilization of imaginative methods in the conclusion and visualization of different malignancies. The comparisons with related works highlight the uniqueness and progressions offered by our examination, situating it as a critical commitment to the continuous discourse in disease research. As it pushes ahead, the combination of these imaginative biochemical approaches holds a gigantic commitment for altering clinical works, encouraging customized restorative procedures, and eventually upgrading patient results in the difficult landscape of disease the executives.

REFERENCE

[1] Al-Joufi, F., Setia, A., Salem-Bekhit, M., Sahu, R.K., Alqahtani, F.Y., Widyowati, R. and Aleanizy, F.S. 2022, "Molecular Pathogenesis of Colorectal Cancer with an Emphasis on Recent Advances in Biomarkers, as Well as Nanotechnology-Based Diagnostic and Therapeutic Approaches", Nanomaterials, vol. 12, no. 1, pp. 169.

[2] Ana Julia Aguiar, d.F., Rhafaela, L.C., Muriele, B.V., Calfa, S., Cassio Murilo Trovo, H.F., Tatiana, T.K., Cristiano de Pádua Souza and Márcia Maria, C.M. 2022, "Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer", International Journal of Molecular Sciences, vol. 23, no. 17, pp. 9952.

[3] Bell, V., Varzakas, T., Psaltopoulou, T. and Fernandes, T. 2024, "Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions", Nutrients, vol. 16, no. 2, pp. 258.

[4] Bourazana, A., Xanthopoulos, A., Briasoulis, A., Magouliotis, D., Spiliopoulos, K., Athanasiou, T., Vassilopoulos, G., Skoularigis, J. and Triposkiadis, F. 2024, "Artificial Intelligence in Heart Failure: Friend or Foe?", Life, vol. 14, no. 1, pp. 145.

[5] Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Himanshu, N.S. and Kumar, S. 2024, "Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies", Biomedicines, vol. 12, no. 1, pp. 201.

[6] Diamantopoulos, M.A., Georgoulia, K.K., Levis, P., Kotronopoulos, G., Stravodimos, K., Kontos, C.K., Avgeris, M. and Scorilas, A. 2024, "28S rRNA-Derived Fragments Represent an Independent Molecular Predictor of Short-Term Relapse in Prostate Cancer", International Journal of Molecular Sciences, vol. 25, no. 1, pp. 239.

[7] Doldi, V., Lecchi, M., Ljevar, S., Colecchia, M., Campi, E., Centonze, G., Marenghi, C., Rancati, T., Miceli, R., Verderio, P., Valdagni, R., Gandellini, P. and Zaffaroni, N. 2022, "Potential of the Stromal Matricellular Protein Periostin as a Biomarker to Improve Risk Assessment in Prostate Cancer", International Journal of Molecular Sciences, vol. 23, no. 14, pp. 7987.

[8] Fan, X., Sun, A.R., Young, R.S.E., Afara, I.O., Hamilton, B.R., Ong, L.J.Y., Crawford, R. and Prasadam, I. 2024, "Spatial analysis of the osteoarthritis microenvironment: techniques, insights, and applications", Bone Research, vol. 12, no. 1, pp. 7.

[9] Ferro, M., Musi, G., Marchioni, M., Maggi, M., Veccia, A., Francesco, D.G., Barone, B., Crocetto, F., Lasorsa, F., Antonelli, A., Schips, L., Autorino, R., Busetto, G.M., Terracciano, D., Lucarelli, G. and Octavian, S.T. 2023, "Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects", International Journal of Molecular Sciences, vol. 24, no. 5, pp. 4615.

[10] Garcia Santa Cruz, B., Husch, A. and Hertel, F. 2023, "Machine learning models for diagnosis and prognosis of Parkinson's disease using brain imaging: general overview, main challenges, and future directions", Frontiers in Aging Neuroscience, .

[11] Gul, N.F., Fatma, H. and Saraf, S.K. 2023, "Vaccines in Breast Cancer: Challenges and Breakthroughs", Diagnostics, vol. 13, no. 13, pp. 2175.

[12] Jiang, S., Wang, T. and Kun-He, Z. 2023, "Data-driven decision-making for precision diagnosis of digestive diseases", Biomedical Engineering Online, vol. 22, pp. 1-30.

[13] Leandrou, S., Lamnisos, D., Bougias, H., Stogiannos, N., Georgiadou, E., Achilleos, K.G., Pattichis, C.S. and Alzheimer's Disease, N.I. 2023, "A cross-sectional study of explainable machine learning in Alzheimer's disease: diagnostic classification using MR radiomic features", Frontiers in Aging Neuroscience, .

[14] Mandair, D., Reis-Filho, J. and Ashworth, A. 2023, "Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology", NPJ Breast Cancer, vol. 9, no. 1, pp. 21.

[15] Márquez-López, A. and Fanarraga, M. 2023, "AB Toxins as High-Affinity Ligands for Cell Targeting in Cancer Therapy", International Journal of Molecular Sciences, vol. 24, no. 13, pp. 11227.

[16] Nevedomskaya, E. and Haendler, B. 2022, "From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer", International Journal of Molecular Sciences, vol. 23, no. 11, pp. 6281.

[17] Nguyen, L.P., Do, D.T., Duong, T.N., Hong, N.L., Tran, T.Q., Ta, V.B. and Dung Thuy, N.P. 2023, "The Utilization of Machine Learning Algorithms for Assisting Physicians in the Diagnosis of Diabetes", Diagnostics, vol. 13, no. 12, pp. 2087.

[18] Orășeanu, A., Brisc, M.C., Maghiar, O.A., Popa, H., Ciprian, M.B., Șolea, S.F., Maghiar, T.A. and Brisc, C. 2023, "Landscape of Innovative Methods for Early Diagnosis of Gastric Cancer: A Systematic Review", Diagnostics, vol. 13, no. 24, pp. 3608.

[19] Pourmadadi, M., Moammeri, A., Shamsabadipour, A., Moghaddam, Y.F., Rahdar, A. and Pandey, S. 2023, "Application of Various Optical and Electrochemical Nanobiosensors for Detecting Cancer Antigen 125 (CA-125): A Review", Biosensors, vol. 13, no. 1, pp. 99.

[20] Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., Fazio, F., Scagnoli, S., Pomati, G., Pantano, F., Perrone, G. and De Falco, E. 2023, "Network approach in liquidomics landscape", Journal of Experimental and Clinical Cancer Research, vol. 42, pp. 1-43.

[21] Sarkar, C., Das, B., Vikram, S.R., Wahlang, J.B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N.M., Das, D., Bidarolli, M. and Hannah, T.S. 2023, "Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development", International Journal of Molecular Sciences, vol. 24, no. 3, pp. 2026.

[22] Shuai, Y., Ma, Z., Ju, J., Tong, W., Gao, S., Kang, Y., Yang, Z., Wang, X., Yue, J. and Yuan, P. 2023, "Liquid-based biomarkers in breast cancer: looking beyond the blood", Journal of Translational Medicine, vol. 21, pp. 1-19.

[23] Slika, H., Karimov, Z., Alimonti, P., Abou-Mrad, T., Fazio, E.D., Alomari, S. and Tyler, B. 2023, "Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues", International Journal of Molecular Sciences, vol. 24, no. 22, pp. 16316.

[24] Toader, C., Dobrin, N., Catalina-Ioana Tataru, Razvan-Adrian Covache-Busuioc, Bogdan-Gabriel Bratu, Glavan, L.A., Horia, P.C., Corlatescu, A.D., David-Ioan Dumitrascu and Alexandru, V.C. 2024, "From Genes to Therapy: Pituitary Adenomas in the Era of Precision Medicine", Biomedicines, vol. 12, no. 1, pp. 23.

[25] Wang, T., Cheng-Yang, L., Tzong-Yi, L., Huang, H., Hsu, J.B. and Chang, T. 2021, "Biomarker Identification through Multiomics Data Analysis of Prostate Cancer Prognostication Using a Deep Learning Model and Similarity Network Fusion", Cancers, vol. 13, no. 11, pp. 2528.

[26] Wang, W., Zheng, Z. and Lei, J. 2023, "CTC, ctDNA, and Exosome in Thyroid Cancers: A Review", International Journal of Molecular Sciences, vol. 24, no. 18, pp. 13767.

[27] Wu, H.H.L., Goldys, E.M., Pollock, C.A. and Saad, S. 2022, "Exfoliated Kidney Cells from Urine for Early Diagnosis and Prognostication of CKD: The Way of the Future?", International Journal of Molecular Sciences, vol. 23, no. 14, pp. 7610.

[28] Wu, Y., Wang, X., Zhang, M. and Wu, D. 2023, "Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas", Molecules, vol. 28, no. 15, pp. 5660.

[29] Yamin, D., Uskoković, V., Abubakar, M.W., Mohammed, D.G., Shazana, H.S., Fatin, H.M., Alfouzan, W.A., Mohammed, A., Alshengeti, A., Almaghrabi, R.H., Al Fares, M.,A., Garout, M., Al Kaabi, N.,A., Alshehri, A.A., Ali, H.M., Rabaan, A.A., Fatimah, A.A., Chan, Y.Y. and [30] Yusof, N.Y. 2023, "Current and Future Technologies for the Detection of Antibiotic-Resistant Bacteria", Diagnostics, vol. 13, no. 20, pp. 3246.

[30] Balasubramanian, S., Raparthi, M., Dodda, S. B., Maruthi, S., Kumar, N., & Dongari, S. (2023). AI-Enabled Mental Health Assessment and Intervention: Bridging Gaps in Access and Quality of Care. PowerTech Journal, 47(3), 81. https://doi.org/10.52783/pst.159